| All news about ALZAMEND NEURO, INC. |
|
| 09:16 a |
Alzheimer’s Neuro, Miller School of Medicine to collaborate on Phase 1/2a Alzheimer’s trial. |
M.T
|
| 08:02 a |
Alzamond Neuro partners with Miller School of Medicine, Interdisciplinary Stem Cell. |
BU
|
| 12/21 |
Capitalgains Report: Biotech Stocks on the Radar: HALB, ALZN, BIIB, CTIC, VKTX |
AQ
|
| 12/12 |
ALZAMOND NEURO, INC. MANAGEMENT DISCUSSION AND FINANCIAL CONDITION ANALYSIS AND R. |
AQ
|
| 12/12 |
Alzamend Neuro, Inc. It reported second quarter and six month end earnings results. |
C.I
|
| 11/22 |
BitNile Holdings reported third quarter 2022 financial results, including revenue of $10. |
AQ
|
| 11/16 |
Alzamend Neuro, Inc.: Regulation FD Disclosures, Financial Statements and Exhibits (Vol. 8. |
AQ
|
| 11/15 |
Alzheimer’s Neuro CEO Stephen Jackman appears on Fox Business Network to discuss the therapy. |
BU
|
| 11/01 |
Alzamond Neuro Receives FDA ‘Study May Continue’ Letter for Phase I/IIA Trial in Its.. |
AQ
|
| 10/31 |
Alzamend Neuro: Regulation FD Presentation – Form 8-K |
PU
|
|
|
|
|
|
| Sale 2023 |
–
–
–
|
| Net income 2023 |
-14.5 million
–
–
|
| Net debt 2023 |
–
–
–
|
| P/E ratio 2023 |
-3.98x |
| 2023 production |
– |
|
| Capitalization |
57.6 million
57.6 million
–
|
| Cap. / Sale 2023 |
– |
| Cap. / Sale 2024 |
– |
| of Employees Nbr |
6 |
| Free-floating |
57.9% |
|
| Chart ALZAMEND NEURO, INC. |
|
Duration:
Time:
|
 |
|
|
Technical Analysis Trends ALZAMEND NEURO, INC.
|
short term |
Medium time |
long term |
| Trends |
Carrier |
Carrier |
Carrier |
The evolution of the income statement
|
|
| Average communication |
Buy it |
| The number of analysts |
1 |
| Last close price |
0.60 dollars |
| Average target price |
7,00 dollars |
| The spread / average target |
1071% |
|
.
[ad_2]
